What the study found
The review found that liver-on-a-chip models have advanced and are being used in both academic and commercial settings. The authors compare different designs, cellular compositions, and levels of complexity across these models.
Why the authors say this matters
The authors say advanced liver-on-a-chip models could be useful in preclinical workflows. They suggest these models have the potential to decrease research and development expenses and reduce or even replace animal testing, while improving the safety and efficacy of new therapies.
What the researchers tested
This is a review article rather than a new experimental study. The authors surveyed recent academic and commercial liver-on-a-chip models, examined their designs and cellular compositions, and performed a systematic comparison of the models.
What worked and what didn't
The review states that liver-on-a-chip technology has proven useful in drug development and in more advanced applications. It also discusses the advantages and disadvantages of different model complexities, along with their current challenges and future perspectives.
What to keep in mind
The abstract does not provide specific experimental results from a single model, and it does not name detailed limitations for the reviewed platforms. The paper is a summary and comparison of existing models, so its conclusions depend on the studies and products it reviewed.
Key points
- The paper reviews recent academic and commercial liver-on-a-chip models.
- It compares model designs, cellular compositions, and complexity.
- The authors say these models may help reduce R&D costs and animal testing.
- The review describes both advantages and disadvantages of model complexity.
- It also discusses current challenges and future perspectives in the field.
Disclosure
- Research title:
- Review compares academic and commercial liver-on-a-chip models
- Authors:
- Zineb Benzait, Özlem Tomsuk, Aliakbar Ebrahimi, Hamed Ghorbanpoor, Ceren Özel, Reza Didarian, Bahar Demir Cevizlidere, Murat Kaya, Tamer Gur, Nigar Gasimzade, Fulya Büge Ergen, Ahmet Emin Topal, Shadab Dabagh, Roshan Javanifar, Nuran Abdullayeva, Onur Uysal, Ayla Eker Sariboyaci, Fatma Doğan Güzel, Shabir Hassan, Huseyin Avci
- Institutions:
- Ankara Yıldırım Beyazıt University, Ankara Yıldırım Beyazıt University, Ankara Yıldırım Beyazıt University, Bahçeşehir University, Brigham and Women's Hospital, Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Cellular Therapeutics (United Kingdom), Composite Components (Czechia), Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Eskişehir Osmangazi University, Harvard University, Institut de Recherche en Cancérologie de Montpellier, Institute of Polymers, Karadeniz Technical University, Khalifa University of Science and Technology, Middle East Technical University, National Research Council, Nello Carrara Institute of Applied Physics, Polymer Research Institute, Stem Cell Institute, Stem Cell Institute, Stem Cell Institute, Stem Cell Institute, Stem Cell Institute, Université de Montpellier, University of Konstanz, University of Pharmacy Mandalay, Yakut Scientific Research Institute of Agriculture
- Publication date:
- 2026-02-02
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.